NEW YORK, Jan. 24, 2021 /PRNewswire/ --
Change Healthcare Inc. CHNG
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CHNG to Optum for $25.75 per share.
If you are a investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Coherent, Inc. COHR - Lumentum Holdings Inc. LITE
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of COHR to LITE for $100.00 per share and 1.1851 LITE shares per share.
If you are a investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
CounterPath Corporation (NASDAQ CM: CPAH)
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CPAH to Alianza, Inc. for $3.49 per share.
If you are a CPAH investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780.
Magellan Health, Inc. MGLN
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MGLN to Centene Corporation for $95.00 per share.
If you are a investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Navistar International Corporation NAV
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of NAV to Traton for $44.50 per share.
If you are an investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Obalon Therapeutics, Inc. OBLN
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of OBLN with ReShape Lifesciences Inc.
If you are a investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Oxford Immunotec Global PLC OXFD
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of OXFD to PerkinElmer, Inc. for $22.00 per share.
If you are a investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Watford Holdings Ltd. WTRE
Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of WTRE to Arch Capital Group for $31.10 per share.
If you are an investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING.© 2021 Lifshitz Law Firm, P.C. The law firm responsible for this advertisement is Lifshitz Law Firm, P.C., 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law Firm, P.C.
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com
View original content:http://www.prnewswire.com/news-releases/lifshitz-law-firm-pc-announces-investigation-of-chng-cohr-lite-cpah-mgln-nav-obln-oxfd-and-wtre-301213600.html
SOURCE Lifshitz Law Firm
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.